These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 17459076)

  • 1. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.
    van de Linde P; Vd Boog PJ; Tysma OM; Elliott JF; Roelen DL; Claas FH; de Fijter JW; Roep BO
    Clin Exp Immunol; 2007 Jul; 149(1):56-62. PubMed ID: 17459076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplantation GAD-autoantibody status to guide prophylactic antibody induction therapy in simultaneous pancreas and kidney transplantation.
    Ringers J; van der Torren CR; van de Linde P; van der Boog PJ; Mallat MJ; Bonifacio E; Roep BO; de Fijter JW
    Transplantation; 2013 Oct; 96(8):745-52. PubMed ID: 23912172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
    Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
    Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results.
    Schulz T; Flecken M; Kapischke M; Busing M
    Transplant Proc; 2005 May; 37(4):1818-20. PubMed ID: 15919476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
    Abou-Jaoude MM; Ghantous I; Almawi WY
    Mol Immunol; 2003 Jul; 39(17-18):1083-8. PubMed ID: 12835081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid.
    Uemura T; Schaefer E; Hollenbeak CS; Khan A; Kadry Z
    Transpl Int; 2011 Jul; 24(7):640-50. PubMed ID: 21429047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.
    Carlsen J; Johansen M; Boesgaard S; Andersen CB; Arendrup H; Aldershvilet J; Mortensen SA
    J Heart Lung Transplant; 2005 Mar; 24(3):296-302. PubMed ID: 15737756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
    Hao WJ; Zong HT; Cui YS; Zhang Y
    Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of induction immunosuppression with anti-IL2-R monoclonal antibody 33B3.1 and rabbit antithymocyte globulin following simultaneous pancreas and kidney transplantation.
    Cantarovich D; Paineau J; Le Mauff B; Karam G; Yaques Y; Hourmant M; Dantal J; Baatard R; Soulillou JP
    Transplant Proc; 1992 Jun; 24(3):911. PubMed ID: 1604665
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
    Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J
    J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab and ATG versus ATG in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous [correction of simultaneus] pancreas-kidney transplantation: analysis of early outcome.
    Dette K; Woeste G; Schwarz R; Wullstein C; Bechstein WO
    Transplant Proc; 2002 Aug; 34(5):1909-10. PubMed ID: 12176624
    [No Abstract]   [Full Text] [Related]  

  • 14. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years.
    Stratta RJ; Alloway RR; Lo A; Hodge EE
    Transplant Proc; 2005 Oct; 37(8):3531-4. PubMed ID: 16298651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interleukin 2 monoclonal antibody following simultaneous pancreatic and kidney transplantation: a randomized trial vs rabbit antithymocyte globulin.
    Cantarovich D; Hourmant M; Dantal J; Baatard R; Le Mauff B; Jacques Y; Paineau J; Murat A; Soulillou JP
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1366. PubMed ID: 8442143
    [No Abstract]   [Full Text] [Related]  

  • 16. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. I. Results after combined pancreas and kidney transplantation.
    Cantarovich D; Le Mauff B; Hourmant M; Dantal J; Baatard R; Denis M; Jacques Y; Karam G; Paineau J; Soulillou JP
    Transplantation; 1994 Jan; 57(2):198-203. PubMed ID: 8310507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation.
    Kirchner VA; Suszynski TM; Radosevich DM; Humar A; Dunn TB; Hill MJ; Finger EB; Sutherland DE; Kandaswamy R
    Transplant Proc; 2010; 42(6):2003-5. PubMed ID: 20692392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
    Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.